Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients.
We report herein on two male liver transplant (LT) recipients who presented with cyclosporine (CsA)-related gynecomastia 6 and 10 months after transplantation. The clinical workup showed increased luteinizing hormone (LH), associated with a slight reduction in testosterone blood levels in one patient and increased prolactin levels in the other. After excluding concomitant primary endocrine and/or malignant disease, conversion to tacrolimus (TAC) was performed resulting in clinical improvement of gynecomastia and return of hormone blood levels to normal range within 3 months. Our report confirms a putative role of CsA in post-LT gynecomastia, reversible however upon conversion to TAC.
Iaria
G
G
Liver Transplant Unit, University of Pisa, Cisanello Hospital, Pisa, Italy.
Urbani
L
L
Catalano
G
G
De Simone
P
P
Carrai
P
P
Petruccelli
S
S
Morelli
L
L
Coletti
L
L
Garcia
C
C
Liermann
R
R
Mosca
F
F
Filipponi
F
F
D006528:Carcinoma, Hepatocellular / Q000601:surgery; D015209:Cholangitis, Sclerosing / Q000601:surgery; D016572:Cyclosporine / Q000009:adverse effects*; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D011388:Prolactin / Q000097:blood; D016559:Tacrolimus / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood
D007166:Immunosuppressive Agents; D013739:Testosterone; D016572:Cyclosporine; D011388:Prolactin; D007986:Luteinizing Hormone; D016559:Tacrolimus